AU2001255537A1 - Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs - Google Patents

Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs

Info

Publication number
AU2001255537A1
AU2001255537A1 AU2001255537A AU5553701A AU2001255537A1 AU 2001255537 A1 AU2001255537 A1 AU 2001255537A1 AU 2001255537 A AU2001255537 A AU 2001255537A AU 5553701 A AU5553701 A AU 5553701A AU 2001255537 A1 AU2001255537 A1 AU 2001255537A1
Authority
AU
Australia
Prior art keywords
amphetamine
drugs
monoclonal antibody
problems associated
medical problems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001255537A
Inventor
Philip Abraham
Frank Ivy Carroll
Samuel M. Owens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arkansas
Original Assignee
University of Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arkansas filed Critical University of Arkansas
Publication of AU2001255537A1 publication Critical patent/AU2001255537A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2001255537A 2000-04-20 2001-04-20 Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs Abandoned AU2001255537A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19890200P 2000-04-20 2000-04-20
US60198902 2000-04-20
PCT/US2001/012899 WO2001081424A1 (en) 2000-04-20 2001-04-20 Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs

Publications (1)

Publication Number Publication Date
AU2001255537A1 true AU2001255537A1 (en) 2001-11-07

Family

ID=22735353

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001255537A Abandoned AU2001255537A1 (en) 2000-04-20 2001-04-20 Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs

Country Status (2)

Country Link
AU (1) AU2001255537A1 (en)
WO (1) WO2001081424A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632929B2 (en) 2000-04-20 2009-12-15 The Board Of Trustees Of The University Of Arkansas Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
EP1331219A1 (en) * 2002-01-23 2003-07-30 Drug Abuse Sciences, Inc. New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them
US20030171435A1 (en) * 2002-01-23 2003-09-11 Drug Abuse Sciences, Inc. New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them
US20050130243A1 (en) * 2003-12-15 2005-06-16 Zheng Yi F. Assay for entactogens
US7037669B2 (en) * 2004-03-22 2006-05-02 Dade Behring Inc. Assays for amphetamine and methamphetamine using stereospecific reagents
US7294649B2 (en) 2004-12-17 2007-11-13 Roche Diagnostics Operatins, Inc. Methamphetamine derivatives and conjugates for immunoassay
WO2007147122A2 (en) 2006-06-15 2007-12-21 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
EP2140263B1 (en) 2007-04-20 2017-01-04 The Board of Trustees of The University of Arkansas Hapten compounds and compositions and uses thereof
US9023353B2 (en) 2013-03-13 2015-05-05 The Board Of Trustees Of The University Of Arkansas Anti-(+)—methamphetamine monoclonal antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4041076A (en) * 1974-10-23 1977-08-09 Hoffmann-La Roche Inc. Immunoassay for pharmacologically active phenethylamines
US4329281A (en) * 1978-06-05 1982-05-11 Hoffmann-La Roche Inc. Hapten compositions
JPH0737986B2 (en) * 1988-03-29 1995-04-26 松下電器産業株式会社 Immunological detection method
US5135863A (en) * 1988-12-23 1992-08-04 Syntex (U.S.A.) Inc. Compositions and methods for determining the presence of amphetamines in a sample suspected of containing amphetamine and/or methamphetamine
CH678394A5 (en) * 1990-08-22 1991-09-13 Cerny Erich H
CA2096495C (en) * 1992-06-16 2002-07-09 Kathy Palmer Ordonez Dual analyte immunoassay
IT1284076B1 (en) * 1996-06-27 1998-05-08 Dox Al Italia Spa F(AB')2 FRAGMENTS AND THEIR IMMUNOGLOBULINS IGG, ACTIVE AS SPECIFIC ANTIBODY TOWARDS DRUGS AND THEIR METABOLITES, AND THEIR
DE19630102A1 (en) * 1996-07-25 1998-01-29 Boehringer Mannheim Gmbh New activated amphetamines

Also Published As

Publication number Publication date
WO2001081424A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
AU4314900A (en) Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
AU1462300A (en) Human pan-hcv human monoclonal antibodies
IL146934A0 (en) Use of antibodies afainst cd20 for the treatment of the graft versus host disease
AU1290001A (en) Antibodies
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU5441000A (en) Human monoclonal antibody
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
AU5497000A (en) Non-malignant disease treatment with ras antagonists
AU1598801A (en) HGF-SF monoclonal antibody combinations
AU2001255537A1 (en) Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
IL151713A0 (en) Monoclonal antibodies to the human ldl receptor, their production and use
IL206565A0 (en) An antibody immunospecific for an igs4 polypeptide
AU2001224818A1 (en) Device for administering liquids
AU2002346581A1 (en) Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
AU2002341839A1 (en) Monoclonal antibodies to the drug tilmicosin and a method for detecting the same
AU2002217212A1 (en) Method for preparing a human monoclonal antibody, fragments thereof or antibodies comprising such fragments, resulting antibodies and use thereof
AU2003210054A1 (en) Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
AU2002325164A1 (en) Receptor, the use thereof, and mouse antibodies
AU2452301A (en) Protein methylarginine-specific antibodies
ITMI20001848A0 (en) DRUGS FOR INCONTINENCE.
AU5046700A (en) Diagnostic monoclonal antibody for LTiGTyersinia pestisLT/iGT
AU2002227175A1 (en) Anti-tenascin monoclonal antibody therapy for lymphoma
GB9927698D0 (en) Therapeutic antibody
GB0016824D0 (en) Human monoclonal antibodies
GB0017139D0 (en) Human monoclonal antibodies